News Categories
Resources For Living
Mesothelioma Forum
Legal Help Blog
Find a Doctor Near You
Mesothelioma Blog
Latest News
- Mesothelin Finding Could Lead to Early Detection of Mesothelioma
- New York Attorney Calls for International Ban on Mesothelioma-Causing Asbestos
- Protein Can be Reliable for Diagnosing Malignant Mesothelioma
- Biomarker Successes Remain Elusive For Mesothelioma and Cancer Researchers
- Avastin May Not be Effective for Breast Cancer, But is Still an Option for Mesothelioma
- Options for Funding Mesothelioma Research
- Golf Outing to Raise Funds for Mesothelioma Research
- 3 Year Mesothelioma Survivor Stays Busy Raising Awareness of the Disease
- MesotheliomaHelp Website Offers Mesothelioma-Related FAQs
- CDMRP System Offers Funding Opportunity to Help Military Mesothelioma Sufferers
Monday, November 30, 2009
A researcher at Van Andel Research Institute in Grand Rapids, Michigan has received a $1.3 million grant from the NIH to study how tumors develop a resistance to chemotherapy. Initially, the research will focus on colon cancer.
Researchers hope that the result of the study will lead to the development of additional screening and treatment methods for other cancers as well. Dr. MacKeigan, the grant recipient, says “if the tumors are resistant to chemotherapy, the cancer is more likely to survive long enough to spread and become more deadly.”
During the five-year study Dr. MacKeigan will assess how various enzymes contribute to determining whether tumor cells will survive during chemotherapy treatment.
Based in Grand Rapids, Michigan, Van Andel Research Institute is the research arm of VAI and is “dedicated to probing the genetic, cellular and molecular origins of cancer, Parkinson and other diseases and working to translate those findings into effective therapies.”
© MesotheliomaHelp.Net. All Rights Reserved. Reprinting or republication of this article or any portion of its content is permitted but must include the MesotheliomaHelp.Net link.
Labels: Research News
posted by Nancy Meredith at 8:55 AM
